RxDoctor Payments Data

Perminder Grewal, MD

Cardiology · Stony Point, NYNPI 1053381715

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (53.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Astrazeneca UK Limited accounts for 66.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $14,774 and has fallen 95.9% since, to $602 in 2025. Among cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,996in general payments, 2019–2025

Across 67 payments — averaging $283.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$13K
  • Boston Scientific$5K
  • AstraZeneca$485
  • Stryker$485
  • Impulse Dynamics (USA) Inc.$223
  • E.r. Squibb & Sons, L.L.C.$200
  • plus $312 from 5 others

What the payments were for

  • Consulting fees$3,48818%
  • Travel & lodging$10,24354%
  • Food & beverage$5,26628%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,996 in reported general payments places this provider in the 90th percentile of 112 cardiology providers in New York.

See all cardiology providers in New York

Medicare billing

Part B allowed, 2024
$202,749
Medicare patients
564
Services billed
2,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$240,805
EntrestoSacubitril/Valsartan67$87,711
XareltoRivaroxaban50$64,537
MultaqDronedarone Hcl18$23,525
Repatha SureclickEvolocumab26$22,990
Metoprolol Succinate455$8,171
Ezetimibe137$4,052
Rosuvastatin Calcium241$4,042
Atorvastatin Calcium375$3,597
Valsartan89$3,284
Diltiazem 24hr Er (Cd)Diltiazem Hcl33$2,847
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide35$2,320
Ranolazine ErRanolazine18$2,290
Nebivolol Hcl26$2,203
Amlodipine Besylate360$1,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$14$64,53750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 cardiology providers in New York.

Other cardiology in Stony Point

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →